OLMA earnings analysis
What we found in OLMA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q text provides limited current-period financial statement detail, but it reports a $63.2 million quarterly net loss versus $43.8 million a year earlier and an accumulated deficit of $713.8 million. Olema continues to invest in multiple clinical programs, but management states that existing cash, cash equivalents and marketable securities will not fund all activities required to complete palazestrant and OP-3136 development. Funding needs, clinical execution, third-party manufacturing dependence and potentially substantial pharmaceutical tariffs create a negative risk/reward profile, with no quantitative financial guidance provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Pipeline investment continues
- Olema reported net losses of $63.2 million for the three months ended June 30, 2026, compared with $43.8 million in the comparable 2025 period. The company states that losses are expected to continue for the foreseeable future.
- Clinical organization expanded
- The company had 150 full-time employees as of June 30, 2026, including 39 employees with Ph.D. or M.D. degrees, supporting concurrent clinical development programs for palazestrant and OP-3136.
- Debt maturity extended
- The loan facility maturity date was extended to January 1, 2029, with potential further extension to July 1, 2029 if specified development or financing milestones occur.
- Controls remain effective
- Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026, and reported no material change in internal control over financial reporting during the quarter.
- No material litigation or sales
- The company reported no material legal proceedings and no unregistered equity sales during the period covered by the report.
- Multiple clinical programs advancing
- Olema continued development of palazestrant across multiple indications, including OPERA-02, a Phase 3 trial combining palazestrant with ribociclib, and clinical development of OP-3136.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Funding and going-concern risk
- The company has accumulated a deficit of $713.8 million as of June 30, 2026 and states that existing cash, cash equivalents and marketable securities will not fund all activities necessary to complete development of palazestrant and OP-3136.
- Debt covenant and default risk
- Olema had an outstanding liability of $3.0 million under its credit facility as of December 31, 2025. The loan agreement contains covenants and customary events of default that could permit acceleration of repayment obligations.
- Tariffs may raise trial costs
- The company states that tariffs of up to 100% on certain patented pharmaceuticals and associated ingredients are scheduled to become effective September 29, 2026, unless reduced, modified or terminated. Management expects tariffs to increase R&D costs and potentially disrupt clinical-trial supply chains.
- Clinical and regulatory execution
- Olema has no products approved for commercial sale and has never completed a pivotal clinical trial or submitted an NDA. Failure of palazestrant or OP-3136 clinical development would prevent product revenue generation.
- Third-party supply concentration
- The company relies on third-party manufacturers and states that raw materials for palazestrant and OP-3136 are sourced in some cases from a single-source supplier, creating potential for clinical-trial delays or interruptions.
- Potential reporting-cost increase
- Olema expects that it will no longer qualify as a smaller reporting company based on its market value at the end of the second fiscal quarter of 2026. Losing that status could increase legal, accounting and financial compliance costs.
What they said about what is next.
No quantitative revenue or EPS guidance is provided in the supplied 10-Q text. The filing states that the company does not anticipate generating product-sale revenue for the next several years, if ever.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 12, 2026
- Olema Pharmaceuticals reported a significant increase in net loss, reaching $53.1 million in Q1 2026 compared to $30.4 million in Q1 2025, with cash reserves of $505.3 million. The company continues to focus on…
- 10-K · March 16, 2026
- Olema is a clinical-stage oncology company advancing its lead oral ER CERAN/SERD palazestrant through pivotal development and an early-stage KAT6 program (OP-3136). The 10-K highlights clear clinical timelines (OPERA-01…
- 10-K · March 18, 2025
- Olema is a clinical‑stage biopharmaceutical company advancing palazestrant (OP‑1250) in a pivotal Phase 3 (OPERA‑01) with anticipated top‑line results in 2026 and preparing a Phase 3 combination trial (OPERA‑02) with…
- 10-Q · May 8, 2024
- Olema reported no product revenue and a net loss of $30,970,000 (net loss per share $0.56) for the three months ended March 31, 2024, driven by higher R&D spending. Cash, cash equivalents and marketable securities…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing OLMA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever